Strategic Vision
GENATLANTICA as the First Commercial Asset of the Lynch Group in Europe
European Commercial Programme
GENATLANTICA represents the first tangible commercial deployment of the Lynch Group’s research heritage in the European market. Operating as the dedicated European entity (OpCo), GENATLANTICA holds an exclusive technology licence from REGENEVIA LLC (HoldCo), the group’s research and intellectual property holding company based in Delaware, USA.
The programme is currently in its active launch phase, with EUCIRCADIAN as the flagship product — a circadian-based longevity nutraceutical designed, formulated, and manufactured in Europe under strict EU regulatory compliance.
Market Strategy
GENATLANTICA’s go-to-market strategy is built on a focused geographic pilot and a multi-channel distribution approach:
| Element | Detail |
|---|---|
| Pilot Geography | Tenerife / Canary Islands — strategic gateway to European and international markets |
| Premium Pharmacies | High-end pharmacy channel for credibility and professional positioning |
| Resort & Hotel Spas | Luxury hospitality partnerships for experiential product discovery |
| Longevity Clinics | Professional wellness and longevity centres as early adopters |
| Selective D2C | Direct-to-consumer e-commerce for qualified, health-conscious buyers |
Regulatory & Compliance Framework
GENATLANTICA operates under a strict compliance-first philosophy. EUCIRCADIAN is classified as a food supplement / nutraceutical under EU regulations. All product claims, labelling, and marketing communications are carefully aligned with applicable regulatory frameworks. No medical, therapeutic, or disease-prevention claims are made.
Corporate Structure
| Entity | Role | Jurisdiction |
|---|---|---|
| REGENEVIA LLC | HoldCo — Research, IP, Patents | Delaware, USA |
| GENATLANTICA | OpCo — European Commercial Operations | European Union |
| Lynch Group | Consortium — Unified Strategic Direction | International |
Future Optionality
Beyond EUCIRCADIAN, the REGENEVIA research pipeline offers significant strategic optionality for future product development. The group’s portfolio of five USPTO patent applications in epigenetic rejuvenation, autologous tissue engineering, and personalised biological formulations represents a deep well of innovation that GENATLANTICA may draw upon as the European market develops and regulatory pathways mature.
For partnership and investment enquiries, please contact: business@regenevia.bio